Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 13, 2005
Last updated: September 25, 2014
Last verified: September 2014

The primary objective of this study is to determine if more diagnoses of lung cancer are obtained from the cytological evaluation of sputum expectorated following a single inhaled dose of UTP compared to sputum expectorated following a single inhaled dose of placebo in patients suspected of having lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Parallel Group Study of Uridine 5'-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Proportion of lung cancers (malignancies) diagnosed by sputum cytology

Secondary Outcome Measures:
  • Proportion of centrally and peripherally located lung cancers diagnosed by sputum cytology;
  • Proportion of small and large lung cancers diagnosed by sputum cytology;
  • Proportion of lung cancers of various cell types, stages and resectability diagnosed by sputum cytology;
  • Wet weight of sputum expectorated;
  • Macrophage content of sputum

Estimated Enrollment: 700
Study Start Date: April 2001
Study Completion Date: December 2003
Primary Completion Date: December 2003 (Final data collection date for primary outcome measure)


Inclusion Criteria:

  • be suspected of having primary lung cancer based upon chest radiograph(s), CT scan(s), or PET scan(s) and with symptom, risk profile, or history suggestive of malignancy
  • have FEV1 greater than or equal to 40% predicted normal for age and height

Exclusion Criteria:

  • have obtained a confirmed diagnosis for the current suspicious lung tumor
  • have been treated for the current, suspicious tumor except in cases in which the current lesion is the recurrence of the same tumor (same location) for which treatment was administered no less than 180 days prior to screening
  • have undergone a bronchoscopic examination or pulmonary fine needle aspiration biopsy within 4 days prior to dosing, or have undergone sputum induction within 3 days prior to dosing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00210080

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00210080     History of Changes
Other Study ID Numbers: 01-312
Study First Received: September 13, 2005
Last Updated: September 25, 2014
Health Authority: United States: Food and Drug Administration processed this record on March 03, 2015